<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nProf. Dr. Ancuceanu Robert<\/strong><\/span>
U.M.F. “Carol Davila”, Bucure\u015fti<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.14″][et_pb_column type=”4_4″ _builder_version=”3.19.14″][et_pb_text _builder_version=”3.19.18″]Inhibitori ai JAK kinazei \u00een tratamentul alopeciei areata<\/span>
\n Autor: Robert Ancuceanu<\/span><\/p>\nDe la sf\u00e2r\u0219itul anului 2017 \u0219i p\u00e2n\u0103 \u00een prezent exist\u0103 un interes tot mai mare legat de utilizarea inhibitorilor JAK kinazei \u00een tratamentul mai multor afec\u021biuni dermatologice, printre care \u0219i alopecia. Poten\u021biale beneficii terapeutice ale inhib\u0103rii c\u0103ii de semnalizare JAK-STAT au fost publicate \u00een rapoarte individuale de caz, mici serii de caz, studii clinice deschise (pe e\u0219antioane mici de subiec\u021bi) \u0219i un studiu randomizat, placebo-controlat. Inhibitori ai JAK kinazei deja autoriza\u021bi (tofacitinib, baricitinib), dar \u0219i inhibitori \u00eenc\u0103 neautoriza\u021bi (PF-06651600, ATI-501 sau CTP-543, care este o versiune modificat\u0103 a ruxolitinib), cu diverse afinit\u0103\u021bi \u0219i selectivit\u0103\u021bi pentru diferitele subtipuri ale JAK kinazei (JAK 1, JAK2, JAK3 sau TYK2) sunt \u00een prezent evalua\u021bi \u00een studii clinice, \u00een principal \u00een alopecia areata. O interogare computerizat\u0103 Medline utiliz\u00e2nd cuvinte-cheie relevante a identificat 83 de publica\u021bii poten\u021bial relevante pentru subiectt. Un exerci\u021biu de explorare a textului rezumatelor (text mining) a identificat un interes mult mai mare pentru eficacitate, dec\u00e2t pentru siguran\u021b\u0103 (de ex. termenul \u201cefficacy\u201d este men\u021bionat de 39 de ori \u0219i \u201ceffective\u201d de 18 ori, \u00een timp ce termenul \u201csafety\u201d este utilizat de 21 de ori, iar \u201csafe\u201d de numai 4 ori (adic\u0103 o frecven\u021b\u0103 relativ\u0103 a termenilor de eficacitate \u0219i sigurna\u021b\u0103 de cca. 2:1). Un \u201enor de cuvinte\u201c (wordcloud) care prezint\u0103 succint termenii cei mai frecven\u021bi din rezumatele publicate \u00een Medline este prezentat \u00een fig. 1. Principalele medicamente asupra c\u0103rora s-a focalizat interesul p\u00e2n\u0103 acum sunt tofacitinib \u0219i ruxolitinib, \u00eens\u0103 av\u00e2nd \u00een vedere studiile clinice \u00een derulare, este de a\u0219teptat ca gama moleculelor de interes s\u0103 fie mai larg\u0103 \u0219i pentru dermatologie, ca \u0219i pentru reumatologie. Prezentarea rezum\u0103 bazele biologice \u0219i imunologice care explic\u0103 utilizarea inhibitorilor JAK kinazei \u00een alopecia areata, datele de eficacitate \u0219i siguran\u021b\u0103 disponibile \u00een prezent, certitudinile \u0219i incertitudinile referitoare la aceast\u0103 nou\u0103 grup\u0103 de medicamente cu multiple utiliz\u0103ri poten\u021biale \u00een dermatologie.<\/p>\n
![](\"https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/03\/ancuceanu.png\")
Fig. 1
\n <\/p>\n
Inhibitors of JAK kinase in the treatment of alopecia areata<\/span>
\nAuthor: Robert Ancuceanu<\/span><\/p>\nFrom the end of 2017 to the present, there has been a growing interest in the use of JAK kinase inhibitors in the treatment of several dermatological conditions, including alopecia. Potential therapeutic benefits of JAK-STAT signalling pathway inhibition have been reported in individual case reports, small case series, open-label clinical trials (on small samples of subjects), and a randomized placebo-controlled study. Inhibitors of JAK kinase already authorized (tofacitinib, baricitinib), as well as inhibitors still unauthorized (PF-06651600, ATI-501 or CTP-543, which is a modified version of ruxolitinib) with various affinities and selectivities for the various JAK kinase subtypes (JAK 1, JAK2, JAK3 or TYK2) are currently being evaluated in clinical trials, primarily in alopecia areata. A Medline computerized query using relevant keywords identified 83 potentially relevant topics. A text mining exercise has identified a much greater interest in efficacy than in safety (for instance, the term “efficacy” occurs 39 times and “effective” 18 times, while the term “safety” is used 21 times, and “safe” only 4 times (i.e. a relative frequency of efficacy and safety terms of about 2: 1). A wordcloud that summarizes the most common terms in the Medline abstracts is presented in Fig. 1. The main medicinal products that have been of interest to date are tofacitinib and ruxolitinib, but considering the ongoing clinical trials, the range of molecules of interest is expected to be broader for both dermatology and rheumatology. The presentation summarizes the biological and immunological bases that explain the use of JAK kinase inhibitors in alopecia areata, the currently available efficacy and safety data, the certainties and uncertainties about this new group of drugs with multiple potential uses in dermatology.<\/p>\n
Scurt CV<\/span><\/p>\nRobert Ancuceanu este profesor \u00een cadrul Facult\u0103\u0163ii de Farmacie din Bucure\u015fti, unde pred\u0103 Biologie celular\u0103 \u0219i molecular\u0103 \u0219i Botanic\u0103 farmaceutic\u0103 \u0219i ocup\u0103 func\u021bia de prodecan pe probleme de \u00eenv\u0103\u021b\u0103m\u00e2nt universitar de licen\u021b\u0103 \u0219i master. Av\u00e2nd un doctorat \u00een farmacie, un masterat \u00een biostatistic\u0103 \u015fi licen\u0163\u0103 \u00een drept, a lucrat \u00een diferite domenii farmaceutice, de la cel academic la cel industrial \u015fi \u00een cadrul autorit\u0103\u0163ilor de reglementare. A fost director general al Direc\u0163iei Generale Farmaceutice \u015fi Aparatur\u0103 Medical\u0103 din Ministerul S\u0103n\u0103t\u0103\u0163ii \u015fi Vicepre\u015fedinte al Agen\u0163ie Na\u0163ionale a Medicamentului. A fost membru al Comitetului pentru Medicamente de Uz Uman (CHMP) \u015fi al Comitetului Pediatric (PDCO) \u015fi membru altern (supleant) al Comitetului pentru Medicamente pe baz\u0103 de Plante din cadrul Agen\u0163iei Europene a Medicamentului (EMA), precum \u015fi membru \u00een mai multe comitete sau grupuri de lucru din domeniul farmaceutic. A publicat 47 articole \u015ftiin\u0163ifice, este autor a dou\u0103 c\u0103r\u0163i \u015fi co-autor la alte patru. Pe l\u00e2ng\u0103 interesul s\u0103u larg pentru toate aspectele domeniului farmaceutic, Robert se consider\u0103 un renascentist \u00eent\u00e2rziat, fiind interesat \u015fi de drept, istorie, muzic\u0103, biostatistic\u0103, sociologie \u015fi literatur\u0103.<\/span><\/p>\n Fig. 1[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Scurt CV Robert Ancuceanu este profesor \u00een cadrul Facult\u0103\u0163ii de Farmacie din Bucure\u015fti, unde pred\u0103 Biologie celular\u0103 \u0219i molecular\u0103 \u0219i Botanic\u0103 farmaceutic\u0103 \u0219i ocup\u0103 func\u021bia de prodecan pe probleme de \u00eenv\u0103\u021b\u0103m\u00e2nt universitar de licen\u021b\u0103 \u0219i master. Av\u00e2nd un doctorat \u00een farmacie, un masterat \u00een biostatistic\u0103 \u015fi licen\u0163\u0103 \u00een drept, a lucrat \u00een diferite domenii farmaceutice, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-842","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=842"}],"version-history":[{"count":10,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842\/revisions"}],"predecessor-version":[{"id":5297,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842\/revisions\/5297"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Prof. Dr. Ancuceanu Robert<\/strong><\/span>
U.M.F. “Carol Davila”, Bucure\u015fti<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.14″][et_pb_column type=”4_4″ _builder_version=”3.19.14″][et_pb_text _builder_version=”3.19.18″]Inhibitori ai JAK kinazei \u00een tratamentul alopeciei areata<\/span>
\n Autor: Robert Ancuceanu<\/span><\/p>\nDe la sf\u00e2r\u0219itul anului 2017 \u0219i p\u00e2n\u0103 \u00een prezent exist\u0103 un interes tot mai mare legat de utilizarea inhibitorilor JAK kinazei \u00een tratamentul mai multor afec\u021biuni dermatologice, printre care \u0219i alopecia. Poten\u021biale beneficii terapeutice ale inhib\u0103rii c\u0103ii de semnalizare JAK-STAT au fost publicate \u00een rapoarte individuale de caz, mici serii de caz, studii clinice deschise (pe e\u0219antioane mici de subiec\u021bi) \u0219i un studiu randomizat, placebo-controlat. Inhibitori ai JAK kinazei deja autoriza\u021bi (tofacitinib, baricitinib), dar \u0219i inhibitori \u00eenc\u0103 neautoriza\u021bi (PF-06651600, ATI-501 sau CTP-543, care este o versiune modificat\u0103 a ruxolitinib), cu diverse afinit\u0103\u021bi \u0219i selectivit\u0103\u021bi pentru diferitele subtipuri ale JAK kinazei (JAK 1, JAK2, JAK3 sau TYK2) sunt \u00een prezent evalua\u021bi \u00een studii clinice, \u00een principal \u00een alopecia areata. O interogare computerizat\u0103 Medline utiliz\u00e2nd cuvinte-cheie relevante a identificat 83 de publica\u021bii poten\u021bial relevante pentru subiectt. Un exerci\u021biu de explorare a textului rezumatelor (text mining) a identificat un interes mult mai mare pentru eficacitate, dec\u00e2t pentru siguran\u021b\u0103 (de ex. termenul \u201cefficacy\u201d este men\u021bionat de 39 de ori \u0219i \u201ceffective\u201d de 18 ori, \u00een timp ce termenul \u201csafety\u201d este utilizat de 21 de ori, iar \u201csafe\u201d de numai 4 ori (adic\u0103 o frecven\u021b\u0103 relativ\u0103 a termenilor de eficacitate \u0219i sigurna\u021b\u0103 de cca. 2:1). Un \u201enor de cuvinte\u201c (wordcloud) care prezint\u0103 succint termenii cei mai frecven\u021bi din rezumatele publicate \u00een Medline este prezentat \u00een fig. 1. Principalele medicamente asupra c\u0103rora s-a focalizat interesul p\u00e2n\u0103 acum sunt tofacitinib \u0219i ruxolitinib, \u00eens\u0103 av\u00e2nd \u00een vedere studiile clinice \u00een derulare, este de a\u0219teptat ca gama moleculelor de interes s\u0103 fie mai larg\u0103 \u0219i pentru dermatologie, ca \u0219i pentru reumatologie. Prezentarea rezum\u0103 bazele biologice \u0219i imunologice care explic\u0103 utilizarea inhibitorilor JAK kinazei \u00een alopecia areata, datele de eficacitate \u0219i siguran\u021b\u0103 disponibile \u00een prezent, certitudinile \u0219i incertitudinile referitoare la aceast\u0103 nou\u0103 grup\u0103 de medicamente cu multiple utiliz\u0103ri poten\u021biale \u00een dermatologie.<\/p>\n
Fig. 1
\n <\/p>\n
Inhibitors of JAK kinase in the treatment of alopecia areata<\/span>
\nAuthor: Robert Ancuceanu<\/span><\/p>\nFrom the end of 2017 to the present, there has been a growing interest in the use of JAK kinase inhibitors in the treatment of several dermatological conditions, including alopecia. Potential therapeutic benefits of JAK-STAT signalling pathway inhibition have been reported in individual case reports, small case series, open-label clinical trials (on small samples of subjects), and a randomized placebo-controlled study. Inhibitors of JAK kinase already authorized (tofacitinib, baricitinib), as well as inhibitors still unauthorized (PF-06651600, ATI-501 or CTP-543, which is a modified version of ruxolitinib) with various affinities and selectivities for the various JAK kinase subtypes (JAK 1, JAK2, JAK3 or TYK2) are currently being evaluated in clinical trials, primarily in alopecia areata. A Medline computerized query using relevant keywords identified 83 potentially relevant topics. A text mining exercise has identified a much greater interest in efficacy than in safety (for instance, the term “efficacy” occurs 39 times and “effective” 18 times, while the term “safety” is used 21 times, and “safe” only 4 times (i.e. a relative frequency of efficacy and safety terms of about 2: 1). A wordcloud that summarizes the most common terms in the Medline abstracts is presented in Fig. 1. The main medicinal products that have been of interest to date are tofacitinib and ruxolitinib, but considering the ongoing clinical trials, the range of molecules of interest is expected to be broader for both dermatology and rheumatology. The presentation summarizes the biological and immunological bases that explain the use of JAK kinase inhibitors in alopecia areata, the currently available efficacy and safety data, the certainties and uncertainties about this new group of drugs with multiple potential uses in dermatology.<\/p>\n
Scurt CV<\/span><\/p>\nRobert Ancuceanu este profesor \u00een cadrul Facult\u0103\u0163ii de Farmacie din Bucure\u015fti, unde pred\u0103 Biologie celular\u0103 \u0219i molecular\u0103 \u0219i Botanic\u0103 farmaceutic\u0103 \u0219i ocup\u0103 func\u021bia de prodecan pe probleme de \u00eenv\u0103\u021b\u0103m\u00e2nt universitar de licen\u021b\u0103 \u0219i master. Av\u00e2nd un doctorat \u00een farmacie, un masterat \u00een biostatistic\u0103 \u015fi licen\u0163\u0103 \u00een drept, a lucrat \u00een diferite domenii farmaceutice, de la cel academic la cel industrial \u015fi \u00een cadrul autorit\u0103\u0163ilor de reglementare. A fost director general al Direc\u0163iei Generale Farmaceutice \u015fi Aparatur\u0103 Medical\u0103 din Ministerul S\u0103n\u0103t\u0103\u0163ii \u015fi Vicepre\u015fedinte al Agen\u0163ie Na\u0163ionale a Medicamentului. A fost membru al Comitetului pentru Medicamente de Uz Uman (CHMP) \u015fi al Comitetului Pediatric (PDCO) \u015fi membru altern (supleant) al Comitetului pentru Medicamente pe baz\u0103 de Plante din cadrul Agen\u0163iei Europene a Medicamentului (EMA), precum \u015fi membru \u00een mai multe comitete sau grupuri de lucru din domeniul farmaceutic. A publicat 47 articole \u015ftiin\u0163ifice, este autor a dou\u0103 c\u0103r\u0163i \u015fi co-autor la alte patru. Pe l\u00e2ng\u0103 interesul s\u0103u larg pentru toate aspectele domeniului farmaceutic, Robert se consider\u0103 un renascentist \u00eent\u00e2rziat, fiind interesat \u015fi de drept, istorie, muzic\u0103, biostatistic\u0103, sociologie \u015fi literatur\u0103.<\/span><\/p>\n Fig. 1[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Scurt CV Robert Ancuceanu este profesor \u00een cadrul Facult\u0103\u0163ii de Farmacie din Bucure\u015fti, unde pred\u0103 Biologie celular\u0103 \u0219i molecular\u0103 \u0219i Botanic\u0103 farmaceutic\u0103 \u0219i ocup\u0103 func\u021bia de prodecan pe probleme de \u00eenv\u0103\u021b\u0103m\u00e2nt universitar de licen\u021b\u0103 \u0219i master. Av\u00e2nd un doctorat \u00een farmacie, un masterat \u00een biostatistic\u0103 \u015fi licen\u0163\u0103 \u00een drept, a lucrat \u00een diferite domenii farmaceutice, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-842","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=842"}],"version-history":[{"count":10,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842\/revisions"}],"predecessor-version":[{"id":5297,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842\/revisions\/5297"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n Autor: Robert Ancuceanu<\/span><\/p>\n
De la sf\u00e2r\u0219itul anului 2017 \u0219i p\u00e2n\u0103 \u00een prezent exist\u0103 un interes tot mai mare legat de utilizarea inhibitorilor JAK kinazei \u00een tratamentul mai multor afec\u021biuni dermatologice, printre care \u0219i alopecia. Poten\u021biale beneficii terapeutice ale inhib\u0103rii c\u0103ii de semnalizare JAK-STAT au fost publicate \u00een rapoarte individuale de caz, mici serii de caz, studii clinice deschise (pe e\u0219antioane mici de subiec\u021bi) \u0219i un studiu randomizat, placebo-controlat. Inhibitori ai JAK kinazei deja autoriza\u021bi (tofacitinib, baricitinib), dar \u0219i inhibitori \u00eenc\u0103 neautoriza\u021bi (PF-06651600, ATI-501 sau CTP-543, care este o versiune modificat\u0103 a ruxolitinib), cu diverse afinit\u0103\u021bi \u0219i selectivit\u0103\u021bi pentru diferitele subtipuri ale JAK kinazei (JAK 1, JAK2, JAK3 sau TYK2) sunt \u00een prezent evalua\u021bi \u00een studii clinice, \u00een principal \u00een alopecia areata. O interogare computerizat\u0103 Medline utiliz\u00e2nd cuvinte-cheie relevante a identificat 83 de publica\u021bii poten\u021bial relevante pentru subiectt. Un exerci\u021biu de explorare a textului rezumatelor (text mining) a identificat un interes mult mai mare pentru eficacitate, dec\u00e2t pentru siguran\u021b\u0103 (de ex. termenul \u201cefficacy\u201d este men\u021bionat de 39 de ori \u0219i \u201ceffective\u201d de 18 ori, \u00een timp ce termenul \u201csafety\u201d este utilizat de 21 de ori, iar \u201csafe\u201d de numai 4 ori (adic\u0103 o frecven\u021b\u0103 relativ\u0103 a termenilor de eficacitate \u0219i sigurna\u021b\u0103 de cca. 2:1). Un \u201enor de cuvinte\u201c (wordcloud) care prezint\u0103 succint termenii cei mai frecven\u021bi din rezumatele publicate \u00een Medline este prezentat \u00een fig. 1. Principalele medicamente asupra c\u0103rora s-a focalizat interesul p\u00e2n\u0103 acum sunt tofacitinib \u0219i ruxolitinib, \u00eens\u0103 av\u00e2nd \u00een vedere studiile clinice \u00een derulare, este de a\u0219teptat ca gama moleculelor de interes s\u0103 fie mai larg\u0103 \u0219i pentru dermatologie, ca \u0219i pentru reumatologie. Prezentarea rezum\u0103 bazele biologice \u0219i imunologice care explic\u0103 utilizarea inhibitorilor JAK kinazei \u00een alopecia areata, datele de eficacitate \u0219i siguran\u021b\u0103 disponibile \u00een prezent, certitudinile \u0219i incertitudinile referitoare la aceast\u0103 nou\u0103 grup\u0103 de medicamente cu multiple utiliz\u0103ri poten\u021biale \u00een dermatologie.<\/p>\n
Fig. 1
\n <\/p>\n
Inhibitors of JAK kinase in the treatment of alopecia areata<\/span> From the end of 2017 to the present, there has been a growing interest in the use of JAK kinase inhibitors in the treatment of several dermatological conditions, including alopecia. Potential therapeutic benefits of JAK-STAT signalling pathway inhibition have been reported in individual case reports, small case series, open-label clinical trials (on small samples of subjects), and a randomized placebo-controlled study. Inhibitors of JAK kinase already authorized (tofacitinib, baricitinib), as well as inhibitors still unauthorized (PF-06651600, ATI-501 or CTP-543, which is a modified version of ruxolitinib) with various affinities and selectivities for the various JAK kinase subtypes (JAK 1, JAK2, JAK3 or TYK2) are currently being evaluated in clinical trials, primarily in alopecia areata. A Medline computerized query using relevant keywords identified 83 potentially relevant topics. A text mining exercise has identified a much greater interest in efficacy than in safety (for instance, the term “efficacy” occurs 39 times and “effective” 18 times, while the term “safety” is used 21 times, and “safe” only 4 times (i.e. a relative frequency of efficacy and safety terms of about 2: 1). A wordcloud that summarizes the most common terms in the Medline abstracts is presented in Fig. 1. The main medicinal products that have been of interest to date are tofacitinib and ruxolitinib, but considering the ongoing clinical trials, the range of molecules of interest is expected to be broader for both dermatology and rheumatology. The presentation summarizes the biological and immunological bases that explain the use of JAK kinase inhibitors in alopecia areata, the currently available efficacy and safety data, the certainties and uncertainties about this new group of drugs with multiple potential uses in dermatology.<\/p>\n Scurt CV<\/span><\/p>\n Robert Ancuceanu este profesor \u00een cadrul Facult\u0103\u0163ii de Farmacie din Bucure\u015fti, unde pred\u0103 Biologie celular\u0103 \u0219i molecular\u0103 \u0219i Botanic\u0103 farmaceutic\u0103 \u0219i ocup\u0103 func\u021bia de prodecan pe probleme de \u00eenv\u0103\u021b\u0103m\u00e2nt universitar de licen\u021b\u0103 \u0219i master. Av\u00e2nd un doctorat \u00een farmacie, un masterat \u00een biostatistic\u0103 \u015fi licen\u0163\u0103 \u00een drept, a lucrat \u00een diferite domenii farmaceutice, de la cel academic la cel industrial \u015fi \u00een cadrul autorit\u0103\u0163ilor de reglementare. A fost director general al Direc\u0163iei Generale Farmaceutice \u015fi Aparatur\u0103 Medical\u0103 din Ministerul S\u0103n\u0103t\u0103\u0163ii \u015fi Vicepre\u015fedinte al Agen\u0163ie Na\u0163ionale a Medicamentului. A fost membru al Comitetului pentru Medicamente de Uz Uman (CHMP) \u015fi al Comitetului Pediatric (PDCO) \u015fi membru altern (supleant) al Comitetului pentru Medicamente pe baz\u0103 de Plante din cadrul Agen\u0163iei Europene a Medicamentului (EMA), precum \u015fi membru \u00een mai multe comitete sau grupuri de lucru din domeniul farmaceutic. A publicat 47 articole \u015ftiin\u0163ifice, este autor a dou\u0103 c\u0103r\u0163i \u015fi co-autor la alte patru. Pe l\u00e2ng\u0103 interesul s\u0103u larg pentru toate aspectele domeniului farmaceutic, Robert se consider\u0103 un renascentist \u00eent\u00e2rziat, fiind interesat \u015fi de drept, istorie, muzic\u0103, biostatistic\u0103, sociologie \u015fi literatur\u0103.<\/span><\/p>\n Scurt CV Robert Ancuceanu este profesor \u00een cadrul Facult\u0103\u0163ii de Farmacie din Bucure\u015fti, unde pred\u0103 Biologie celular\u0103 \u0219i molecular\u0103 \u0219i Botanic\u0103 farmaceutic\u0103 \u0219i ocup\u0103 func\u021bia de prodecan pe probleme de \u00eenv\u0103\u021b\u0103m\u00e2nt universitar de licen\u021b\u0103 \u0219i master. Av\u00e2nd un doctorat \u00een farmacie, un masterat \u00een biostatistic\u0103 \u015fi licen\u0163\u0103 \u00een drept, a lucrat \u00een diferite domenii farmaceutice, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-842","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=842"}],"version-history":[{"count":10,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842\/revisions"}],"predecessor-version":[{"id":5297,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/842\/revisions\/5297"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nAuthor: Robert Ancuceanu<\/span><\/p>\n Fig. 1[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"